Polycythemia vera disease burden: contributing factors, impact on quality of life, and emerging treatment options.

Brady L Stein, Alison R Moliterno, Ramón V Tiu

Annals of hematology 2014 Dec

filter terms:

Polycythemia vera (PV) is a chronic myeloproliferative neoplasm characterized by clonal expansion of a hematopoietic progenitor, erythrocytosis, often leukocytosis and/or thrombocytosis, and nearly always an activating mutation in Janus kinase 2 (JAK2). The PV symptom burden can be considerable, in part driven by small or large vessel thrombotic tendency, splenomegaly, fatigue, pruritus, and a chronic risk of disease transformation to myelofibrosis or acute myeloid leukemia. In addition, patients with PV have an increased risk of mortality compared with the general population that often results from cardiovascular complications or disease transformation. Further, healthcare utilization and costs are higher in patients with PV than noncancer controls. First-line therapy options for high-risk patients may effectively manage PV in some instances; however, some patients do not receive adequate benefit from current treatment options and experience a more severe disease burden as a result. This may be especially true for those patients who are resistant to or intolerant of hydroxyurea or interferon-based therapies. New treatments currently being investigated in phase 3 clinical trials may alleviate disease burden in this patient population.

Citation

Brady L Stein, Alison R Moliterno, Ramón V Tiu. Polycythemia vera disease burden: contributing factors, impact on quality of life, and emerging treatment options. Annals of hematology. 2014 Dec;93(12):1965-76